level 3 semaglutide Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase study semaglutide level 3 Semaglutide 3

The recent approval of tirzepatide, the first dual glucose dependent insulinotropic polypeptide and GLP 1 receptor agonist, challenges the long held assumption that targeting a single hormonal pathway is sufficient for optimal metabolic control

Cav-1 binds to eNOS at the caveolin-scaffolding domain (CSD, a.a

But theres another story unfolding that could have major implications across the consumer goods ecosystem

Am J Health Promot

At the starting 0.25 mg/week dose, effects are usually mild

Head-to-head clinical data from the SURMOUNT-5 trial published in 2024 found that tirzepatide produced approximately 20% greater weight loss than semaglutide at comparable doses